Physician profile
Marcelo E Lancman
NPI 1609857010
$414.22
in general payments reported to CMS, 2019-2025
12 companies · $64.01 in 2025
The $64.01 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.55 · 2020: $53.35 · 2021: $61.20 · 2022: $92.59 · 2023: $16.57 · 2024: $71.95 · 2025: $64.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $95.17 | 2019-2021 | |
| Sk Life Science, INC. | $81.61 | 2020-2022 | |
| Abbvie INC. | $43.51 | 2022-2023 | |
| Ucb, INC. | $40.74 | 2025 | Fintepla, Briviact |
| Aquestive Therapeutics, INC. | $37.39 | 2020 | |
| Alnylam Pharmaceuticals INC. | $24.85 | 2024 | Onpattro |
| Catalyst Pharmaceuticals, INC. | $23.62 | 2024 | |
| Jazz Pharmaceuticals INC. | $23.48 | 2024 | |
| Livanova USA, INC. | $23.27 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $20.58 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcelo Lancman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.